ST荣科 reported revenue of ¥0.24B for the period ended 2026-06-30, -17.0% year on year. Net income was ¥-0.15B, a -61.8% net margin on a 36.0% gross margin. The largest revenue line is 自主产品及服务 at 66% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.24B | -17.0% |
| Gross profit | ¥0.09B | — |
| Operating income | ¥-0.04B | — |
| Net income | ¥-0.15B | — |
| Gross margin | 36.0% | Net margin -61.8% |
| Revenue Q/Q | +24.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自主产品及服务 | ¥0.16B | 66.1% |
| 系统集成 | ¥0.08B | 33.8% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.15B | 64.0% |
| R&D | ¥0.02B | 10.2% |
| SG&A | ¥0.10B | 43.0% |
| Tax & other | ¥0.11B | 44.6% |
| Item | Amount |
|---|---|
| Total assets | ¥1.53B |
| Total liabilities | ¥0.86B |
| Shareholders' equity | ¥0.66B |
| Equity / assets | 43.5% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | 73% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技 ・ 聚飞光电
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies